Suchergebnisse - "O'Connor, Owen A"

PubPharm (24)

1

Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma

enthalten in: British journal of haematology | 2014

von Craig, M. | Hanna, W. | Cabanillas, F. | +4

2

Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib : multicentre, single-arm, phase 2 study

enthalten in: British journal of haematology | 2014

von Wang, M. | Popplewell, L. | Collins, R. | +16

3

Pralatrexate pharmacology and clinical development

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2013

von Marchi, E. | Mangone, M. | Zullo, K. | +1

4

Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma

enthalten in: British journal of haematology | 2012

von Gerecitano, J. | Gounder, S. | Teruya-Feldstein, J. | +9

5

Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2011

von Gerecitano, J. | Portlock, C. | Hamlin, P. | +14

6

Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia

enthalten in: Clinical lymphoma, myeloma & leukemia | 2011

von Sun, J. | Xu, L. | Tseng, H. | +16

7

Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2010

von Marchi, E. | Paoluzzi, L. | Scotto, L. | +4

8

Novel agents in development for peripheral T-cell lymphoma

enthalten in: Seminars in hematology | 2010

von O'Connor, O.

9

Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2010

von Paoluzzi, L. | Scotto, L. | Marchi, E. | +3

10

Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2010

von O'Connor, O. | Portlock, C. | Moskowitz, C. | +16